Takara Bio Inc. (TYO:4974)
Japan · Delayed Price · Currency is JPY 1,142.00
0.00 (0.00%)
Jun 3, 2026, 3:30 PM JST
Takara Bio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 40,318 | 45,039 | 43,505 | 78,142 | 67,699 | |
Revenue Growth (YoY) | -10.48% | 3.53% | -44.33% | 15.43% | 46.90% |
Cost of Revenue | 20,057 | 18,972 | 16,597 | 33,377 | 18,488 |
Gross Profit | 20,261 | 26,067 | 26,908 | 44,765 | 49,211 |
Selling, General & Admin | 18,103 | 16,901 | 15,615 | 15,570 | 14,180 |
Research & Development | 6,806 | 6,897 | 8,324 | 8,575 | 6,109 |
Operating Expenses | 24,949 | 23,804 | 23,905 | 24,224 | 20,309 |
Operating Income | -4,688 | 2,263 | 3,003 | 20,541 | 28,902 |
Interest Expense | -582 | -20 | -23 | -24 | -23 |
Interest & Investment Income | 174 | 300 | 186 | 142 | 122 |
Currency Exchange Gain (Loss) | 52 | -131 | 97 | -120 | -706 |
Other Non Operating Income (Expenses) | 50 | 179 | 140 | 142 | 163 |
EBT Excluding Unusual Items | -4,994 | 2,591 | 3,403 | 20,681 | 28,458 |
Gain (Loss) on Sale of Investments | - | -84 | - | - | - |
Gain (Loss) on Sale of Assets | -58 | -135 | -344 | -97 | -168 |
Asset Writedown | -3,876 | -377 | -207 | - | -5,227 |
Other Unusual Items | -273 | 1 | - | 639 | 4,468 |
Pretax Income | -9,201 | 1,996 | 2,852 | 21,223 | 27,531 |
Income Tax Expense | 353 | 910 | 1,343 | 5,176 | 7,624 |
Earnings From Continuing Operations | -9,554 | 1,086 | 1,509 | 16,047 | 19,907 |
Minority Interest in Earnings | -45 | -45 | -29 | -35 | -58 |
Net Income | -9,599 | 1,041 | 1,480 | 16,012 | 19,849 |
Net Income to Common | -9,599 | 1,041 | 1,480 | 16,012 | 19,849 |
Net Income Growth | - | -29.66% | -90.76% | -19.33% | 107.91% |
Shares Outstanding (Basic) | 120 | 120 | 120 | 120 | 120 |
Shares Outstanding (Diluted) | 120 | 120 | 120 | 120 | 120 |
EPS (Basic) | -79.72 | 8.65 | 12.29 | 132.97 | 164.84 |
EPS (Diluted) | -79.72 | 8.65 | 12.29 | 132.97 | 164.84 |
EPS Growth | - | -29.66% | -90.76% | -19.33% | 107.91% |
Free Cash Flow | -8,993 | -4,027 | -11,067 | 31,150 | -5,418 |
Free Cash Flow Per Share | -74.68 | -33.44 | -91.91 | 258.69 | -44.99 |
Dividend Per Share | - | 17.000 | 17.000 | 42.000 | 33.000 |
Dividend Growth | - | - | -59.52% | 27.27% | 106.25% |
Gross Margin | 50.25% | 57.88% | 61.85% | 57.29% | 72.69% |
Operating Margin | -11.63% | 5.03% | 6.90% | 26.29% | 42.69% |
Profit Margin | -23.81% | 2.31% | 3.40% | 20.49% | 29.32% |
Free Cash Flow Margin | -22.30% | -8.94% | -25.44% | 39.86% | -8.00% |
EBITDA | 633 | 6,744 | 8,024 | 25,276 | 33,051 |
EBITDA Margin | 1.57% | 14.97% | 18.44% | 32.35% | 48.82% |
D&A For EBITDA | 5,321 | 4,481 | 5,021 | 4,735 | 4,149 |
EBIT | -4,688 | 2,263 | 3,003 | 20,541 | 28,902 |
EBIT Margin | -11.63% | 5.03% | 6.90% | 26.29% | 42.69% |
Effective Tax Rate | - | 45.59% | 47.09% | 24.39% | 27.69% |